ISRCTN65155201Completed未知
A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids
The Royal Marsden NHS Foundation Trust (UK)0 sites200 target enrollmentStarted: March 29, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Patients must have a clinical or histological diagnosis of cancer
- •2. Patients whose pain is not controlled on Step 2 (weak opioid) analgesics (as defined by the WHO analgesic ladder) who clinically require a strong opioid
- •3. Patients must be over 18 years of age
- •4. Patients must be able to give written informed consent
- •5. Patients must be willing to undergo genetic screening
Exclusion Criteria
- •Current exclusion criteria as of 23/06/2011:
- •1. Patients with renal failure (1.5x ULN). These patients should be treated with alfentanil as per Palliative Care Clinical Guidelines
- •2. Patients must not currently be taking regular strong opioids
- •3. Patients requiring parenteral administration of opioids
- •4. Patients with predominantly incident pain
- •5. Patients with a clearly defined history of intolerance to morphine or oxycodone
- •6. Patients who are pregnant
- •Previous exclusion criteria:
- •1. Patients with renal failure (1.5 x upper limit of normal [ULN]). These patients should be treated with alfentanil as per palliative care guidelines.
- •2. Patients must not have been taking regular Step 3 analgesics in the last month
- •3. Patients requiring parenteral administration of opioids
- •4. Patients with predominantly neuropathic pain
- •5. Patients with predominantly incident pain
- •6. Patients with a clearly defined history of intolerance to morphine or oxycodone
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids. - RCT Morphine vs Oxycodone: Genetics Study10-30% of cancer patients have an unsuccessful outcome when given oral morphine because of intolerable side effects. Oxycodone is an alternative opioid which is commonly used as a second line opioid. No randomised controlled trials have yet been carried out directly comparing morphine versus oxycodone.EUCTR2005-001660-31-GBThe Royal Marsden Hospital NHS Foundation Trust
Recruiting
Phase 3
Comparison of Results between Open Carpal Tunnel Release and Minimally Invasive Carpal Tunnel Release in Carpal Tunnel Syndrome PatientsPain scoreOpen carpal tunnel releaseMinimally invasive carpal tunnel ReleaseCarpal tunnel syndromeTCTR20220914002/A90
Completed
Not Applicable
A Prospective Randomised Controlled Trial of the Immediate Post-operative Intra-articular Local Anaesthetic Infusion Using Infusion Pump in Total Knee Arthroplasty.PainSigns and Symptoms: PainSigns and SymptomsISRCTN32365985Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)50
Recruiting
Phase 3
A Prospective Randomized Controlled Clinical Trial of Prophylactic Cranial Irradiation in Metastatic HER-2 positive Breast Cancer.Metastatic HER-2 positive breast cancer patientsRisk of brain metastasisHER2 positivePCIMetastatic breast cancerTCTR20170612001Ratchadapiseksompotch research fund235
Completed
Not Applicable
A study to assess the effectiveness of Ayurvedic formulation Guduchi Ghan vati in Covid-19 casesCTRI/2020/07/026840Directorate of AYUSH Government of Madhya Pradesh30